Feb 14,2023

New Biopharma Leaders Survey Provides Exclusive Industry Insight on Current Unmet Needs and Future Plans for Digital Solution Offerings

The respondents of a recent national survey represent pre-commercial, mid-size and large Biopharma companies, with 69% being those with more than $10 billion in annual revenues. The survey and findings analyzed digital solutions in six key areas: Analytics, Real World Evidence (RWE), Enterprise, Clinical Development, Patient Engagement and Digital Therapeutics. Key findings and insights of the report include: investments in digital solutions to address RWE and Clinical Development are shown to be a strategic priority for the next 3 years, and investments in patient engagement solutions are expected to continue during the next 5 years.

#pdt

View Analyst & Ambassador Comments
Go to original news
Feb 22,2023 TOP STORY

Dawn Health, Novartis partner to develop chronic condition management tools

Copenhagen-based digital health company Dawn Health announced a strategic partnership with pharma giant Novartis to develop a chronic condition management platform. Under the collaboration, Dawn and Novartis will build remote monitoring and management tools for chronic conditions where they see unmet need and concerns around disease progression, like multiple sclerosis, hypertension, cardiovascular disease and breast cancer. The platform will include patient mobile apps, symptom monitoring, digital biomarkers, clinical decision support services and virtual clinic offerings geared toward specific diseases and conditions.

COLLABORATION PARTNERSHIP

#r&d

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 27,2023

M2GEN and Zephyr AI Announce Partnership to Better Identify Treatments and Cures for Patients with Cancer

M2GEN, a bioinformatics company accelerating discoveries in oncology research through industry-leading data and analytics, and Zephyr AI, Inc., a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine, today announced a multi-year strategic partnership that will accelerate drug discovery and expanded use investigations for cancer treatments. In this partnership, M2GEN will license its expansive RWD to Zephyr AI, providing the latter with access to the richest clinicogenomic data set available in oncology today. In return, Zephyr AI will become a bioinformatics partner for M2GEN, providing the company with AI and machine learning capabilities to enhance their products and services. 

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 04,2023

Massive Bio Announces Plans to Expand AI Use in Oncology, from Clinical Trial Matching to Drug Matching and Beyond

Massive Bio, a leader in AI-assisted cancer treatment, has announced the launch of a new AI-powered drug matching product in 2023. This product will allow oncologists to proactively identify a broader range of cancer treatment options for their patients, including recently approved drugs and active clinical trials. Furthermore, the drug matching product will help biotech and pharmaceutical companies to better target patients and physicians who require the latest drugs, ultimately improving their go-to-market efficiency. Massive Bio aims to launch its first drug matching product in the first half of 2023 and plans to make it widely available later in the year.

PRODUCT

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Jan 05,2023

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

Tempus, a company that specializes in AI and precision medicine, has announced a prospective study in collaboration with AstraZeneca to identify biomarkers of response in patients with small cell lung cancer. The study, called Sculptor, is currently enrolling patients and is leveraging Tempus' portfolio of molecular profiling offerings.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 05,2023

Turbine’s AI-powered Cancer Cell Simulations Will Be Used to Identify Novel Disease Positioning Strategies in Cancer Research UK’s Latest Biotech Partnership

Cancer Research Horizons, the innovation engine at the core of Cancer Research UK, is collaborating with Turbine, a tech-enabled biotech that leverages its proprietary Simulated Cell platform to address complex diseases. The collaboration will identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons' lead compound CRT'2199.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

Huma acquires Alcedis, one of the world's leading digital clinical trials companies

Huma Therapeutics Limited has acquired Alcedis GmbH, a leading data-driven clinical research and technology company, to establish an advanced clinical trials division that will offer digital solutions throughout the entire development pipeline, from early stages to Phase IV hybrid and fully decentralized trials.

COLLABORATION MERGERS & ACQUISITION

#data & technology

#rwd

#platform

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

GNS Rebrands as Aitia to Focus on AI-Enabled Drug Discovery

GNS, a company that applies causal AI and "Digital Twins" to discover and develop new drugs, has rebranded itself as Aitia. Aitia will focus on using its Gemini Digital Twins to develop breakthrough drugs in various fields, including oncology, neurodegeneration, and immunology.

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

Pharma – 2023 Health IT Predictions

According to Dr. Ofer Sharon, the CEO at OncoHost, there will be significant biotech innovation in the precision oncology sector in 2023. He predicts that more pharmaceutical companies will integrate precision medicine programs into their drug development efforts, and there will be increased regulation on precision medicine solutions and tools that combine machine learning and AI.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 10,2023

Development and external validation of a machine learning-based prediction model for the cancer-related fatigue diagnostic screening in adult cancer patients: a cross-sectional study in China

This study aimed to create a CRF prediction model for cancer patients based on routinely obtained data from electronic health records (EHRs) using the 3P model, and externally validate the model with an independent dataset from another hospital. The study concluded that the 3P-based fatigue prediction model can accurately predict the risk of CRF, and that nonlinear algorithms such as Random Forest and Naive Bayes are more suitable for symptom diagnosis and evaluation.

CLINICAL STUDY

#rwd

#big data

#ml

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY